결핵 진료지침
105. Yanagisawa K, Kanai K, Sato N, Hashimoto T, Takahashi H. Effects of kanamycin in experimental tuberculosis of guinea pigs. Ann N Y Acad Sci 1958;76:88–102.
106. Steenken W Jr, Montalbine V, Thurston Jr. The antituberculous activity of kanamycin in vitro and in the experimental animal (guinea pig). Ann N Y Acad Sci 1958;76:103–8.
107. Wright KW, Renzetti AD Jr, Lunn J, Bunn PA. Observations of the use of kanamycin in patients in a tuberculosis hospital. Ann N Y Acad Sci 1958;76:157–62.
108. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9:e1001300.
109. Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2019;23:645–62.
110. Marrone MT, Venkataramanan V, Goodman M, Hill AC, Jereb JA, Mase SR. Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2013;17:6–16.
111. Kim HJ, Kang CH, Kim YT, Sung SW, Kim JH, Lee SM, et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 2006;28:576–80.
112. Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, et al. Surgery as an adjunctive treatment for multidrug-resistant tuberculosis: an individual patient data meta analysis. Clin Infect Dis 2016;62:887–95.
113. WHO operational handbook on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022.
114. World Health Organization. Treatment of tuberculosis: guidelines for

Ⅲ. 약제내성결핵의 치료 <PAGE>143